PMID: 11605167Oct 18, 2001Paper

Erythrocyte-active agents and treatment of sickle cell disease

Seminars in Hematology
Carlo BrugnaraY Beuzard

Abstract

The sickle hemoglobin (HbS)-containing erythrocyte and its membrane represent a logical target for sickle cell disease therapy. Several antisickling agents which interfere with HbS polymerization have been studied over the last 30 years, but none has overcome the challenge of delivering high concentrations inside the sickle red blood cell without toxicity. The sickle erythrocyte membrane has also been targeted for therapeutic developments. Prevention of sickle cell dehydration by use of specific blockers of ion transport pathways mediating potassium loss from the sickle erythrocyte has been shown to be a feasible strategy in vitro, in vivo in transgenic sickle mice, and in patients. Other approaches have focused on improving the hemorheology of sickle erythrocytes and reducing their abnormal adhesion to endothelial cells. These potential treatments could be used alone or in combination with other approved therapies, such as hydroxyurea.

References

Oct 5, 1978·The New England Journal of Medicine·J Dean, A N Schechter
Oct 1, 1976·The Journal of Clinical Investigation·S E LuxM J Karnovsky
Oct 15, 1975·Journal of Molecular Biology·B C WishnerW E Love
Feb 1, 1976·FEBS Letters·T L ChaoT G Gabuzda
Jan 1, 1992·Free Radical Research Communications·V Udupi, C Rice-Evans
Jan 1, 1990·The American Journal of Pediatric Hematology/oncology·D ChiuB H Lubin
Jan 1, 1989·Annals of the New York Academy of Sciences·C T NoguchiA N Schechter
Jul 1, 1986·The American Journal of the Medical Sciences·N A Lachant, K R Tanaka
Mar 21, 1974·The New England Journal of Medicine·P N GilletteA Cerami
Jul 8, 1966·Science·M Murayama
Dec 1, 1983·British Journal of Haematology·S T Ohnishi
Nov 13, 1980·The New England Journal of Medicine·R M RosaF H Epstein
Apr 1, 1982·European Journal of Biochemistry·M C GarelJ Rosa
Nov 1, 1981·The Journal of Clinical Investigation·L R Berkowitz, E P Orringer
Aug 1, 1995·The American Journal of Physiology·C H JoinerR S Franco
Jun 8, 1995·The New England Journal of Medicine·J LefkovitsE J Topol
Feb 1, 1993·The American Journal of Physiology·C H Joiner
Jun 1, 1996·British Journal of Haematology·R AryaA J Bellingham
Sep 1, 1996·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·H Chen, J Rhodes
Dec 1, 1996·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·B L LopezX Ma
Jun 1, 1997·The Journal of Clinical Investigation·V L LewR M Bookchin
Sep 1, 1997·The Journal of Clinical Investigation·C A HeadW M Zapol
Sep 11, 1997·The New England Journal of Medicine·H F Bunn
Oct 6, 1997·The Journal of Clinical Investigation·L De FranceschiC Brugnara
Jun 2, 1998·Free Radical Biology & Medicine·P BrowneR P Hebbel

❮ Previous
Next ❯

Citations

Nov 12, 2005·Pflügers Archiv : European journal of physiology·Lucia De FranceschiGiorgio Berton
Sep 21, 2002·Lancet·Elliott Vichinsky
Dec 7, 2002·Journal of Pediatric Hematology/oncology·David G Nathan
Jan 22, 2019·European Journal of Haematology·Andrea PiccinOwen P Smith
Apr 30, 2020·Antioxidants·Elena TibaldiLucia De Franceschi
Apr 3, 2008·The Journal of Clinical Investigation·Nathalie SabaaPierre-Louis Tharaux

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.